Use of Nutritional Supplements in Youth with Medicated and Unmedicated Attention-Deficit/Hyperactivity Disorder by Scholle, O. et al.
Use of Nutritional Supplements in Youth with Medicated
and Unmedicated Attention-Deficit/Hyperactivity Disorder
Oliver Scholle, MSc,1 Hannah Jilani, MPH,2 Oliver Riedel, PhD,1 Tobias Banaschewski, MD, PhD,3
Charalambos Hadjigeorgiou, PhD,4 Monica Hunsberger, PhD,5 Isabel Iguacel, MSc,6
De´nes Molna´r, PhD,7 Valeria Pala, Dr Sc,8 Paola Russo, MSc,9 Toomas Veidebaum, PhD,10
Mahmoud Zaqout, MD,11 and Hermann Pohlabeln, PhD12; on behalf of the I.Family Consortium
Abstract
Objective:To find out whether use of nutritional supplements (NUS) differs between children and adolescents with attention-
deficit/hyperactivity disorder (ADHD; medicated or unmedicated), compared with those without the disorder.
Methods: We used cross-sectional data from the population-based I.Family study conducted between 2013 and 2014 in eight
European countries. Parents completed questionnaires and participated in interviews, for example, on health and medical
history of their child. Data from 5067 children and adolescents aged 5–17 years were included. Exposures were medicated
(with ADHD-approved medication) and unmedicated ADHD. The outcome was the use of NUS, measured by use of any or
multiple different NUS. Multivariable logistic regression adjusted for sociodemographics and health determinants was used
to find ADHD-depending differences.
Results: The study sample comprised 4490 children and adolescents without ADHD and 51 medicated and 76 unmedicated
subjects with ADHD. Regarding the use of any NUS, no statistically significant differences were found between children and
adolescents without ADHD (18%) and those with medicated (18%) or unmedicated ADHD (22%). However, discrepancies
appear when considering multiple use of NUS, not reported for any medicated ADHD subject but remarkably often for
unmedicated ADHD subjects (13%), resulting in an adjusted odds ratio of 2.6 (95% confidence interval, 1.2–5.6) when
compared with those without ADHD (5%).
Conclusion: Children and adolescents who were not using medication for treating ADHD potentially took NUS as oral
remedies. Given the potential for a delay of indicated treatments and for use of those NUS which have no proven effectiveness,
pediatricians should actively explore whether NUS have been used to treat ADHD core symptoms, and families should be
informed that the average effect size has to be considered small.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is acommon neurodevelopmental disorder with a worldwide
prevalence of 3.4% in children and adolescents (Polanczyk et al.
2015). Apart from pharmacological treatments with stimulants,
nutritional supplements (NUS), categorized as ‘‘complementary
and alternative treatments,’’ are also commonly used (Chan et al.
2003; Sinha and Efron 2005). Until recently, clinical guidelines on
ADHD either did not explicitly mention complementary and al-
ternative medicine, such as NUS, or reported a lack of evidence for
their use (Taylor et al. 2004; Pliszka and AACAP Work Group
on Quality Issues 2007; Subcommittee on Attention-Deficit/
Hyperactivity Disorder et al. 2011).
However, since 2016, the ADHD guideline by the British Na-
tional Institute for Health and Care Excellence (NICE) clearly has
advised against use of dietary polyunsaturated fatty acid supple-
mentation for treating ADHD (NICE 2018). Research published
after this update of the NICE guideline suggests that polyunsaturated
fatty acids—particularly omega-3 fatty acids from fish oil—might be
effective in reducing the dosage of the ADHD medication (Ko¨nigs
and Kiliaan 2016; Lange et al. 2017). In addition, zinc, iron, and
magnesium might assist in alleviating ADHD symptoms in children
with deficiencies in any of these minerals or with an increased risk
thereof (Bloch and Mulqueen 2014; Lange et al. 2017).
Also, results from a randomized controlled trial indicate that
children with ADHD and comorbid emotional dysregulation may
benefit from certain vitamin/mineral supplementation by improving
emotional regulation, aggression, and general functioning (Ruck-
lidge et al. 2018). Nevertheless, more studies in this area are needed
before the efficacy of these supplements can be properly measured.
The lack of evidence is contrary to the high popularity of com-
plementary and alternative medicine indicated by previous studies.
At the end of the 1990s, more than half of 114 U.S. parents of children
with ADHD in one clinic had reported using complementary and
alternative medicine for their child during the past year (Chan et al.
2003) and in 2003, about two-thirds of parents in Australia reported
ever having used complementary and alternative medicine to treat
their ADHD-affected children (Sinha and Efron 2005). NUS were
among the most common interventions used. However, these studies
did not have a comparison group and used clinical samples usually
representing more severely affected ADHD patients.
Results from the 1999 to 2002 U.S. National Health and Nutri-
tion Examination Surveys (NHANES) indicated that adolescents
with ADHD were more likely to use NUS than those without
ADHD (Gardiner et al. 2008). Use of NUS was generally more
common in those who used prescription drugs. As the study did not
focus on ADHD patients, the influence of using ADHD medication
on the results remained unclear. Furthermore, only participants
aged 11 years and older were included. That age is beyond the
typical ADHD onset and differences might be more pronounced
when younger children are also included.
Moreover, most evidence regarding fish oil as an omega-3-
containing NUS to treat ADHD only emerged starting in the mid-
2000s (Heilskov Rytter et al. 2015). In addition, advertisements
broadly formulating the beneficial effects of such NUS on ADHD
symptoms might have led to an increased use since the publication of
the NHANES data. In fact, use of omega-3 fatty acid supplements
among U.S. children and adolescents increased between 2003 to
2004 and 2013 to 2014 from 0.4% to 2.3% (Qato et al. 2018).
In this study, we aimed to assess differences in use of NUS
among children and adolescents with ADHD compared with those
without the disorder in a population-based sample. The research
question was stimulated by the results of the NHANES study,
where adolescents with ADHD had a slightly higher (10%) use of
any NUS than other adolescents (Gardiner et al. 2008). The study
also showed that adolescents who used prescription drugs were
significantly more likely (37%) to use any NUS (Gardiner et al.
2008). Compared with the NHANES study, our data enabled us to
estimate the effect of use of prescription drugs without considering
medication to treat ADHD. Furthermore, they allowed us to ask a
more specific research question: Is the use of NUS in children and
adolescents with ADHD dependent on whether they are treated
with ADHD medication or not?
Methods
Setting
Data were used from the European I.Family study conducted
between 2013 and 2014 in eight countries (Belgium, Cyprus,
Estonia, Germany, Hungary, Italy, Spain, and Sweden). The study
can be regarded as the second follow-up examination of a
community-based field study on ‘‘Identification and prevention of
Dietary- and lifestyle-induced health Effects In Children and
infantS’’ (IDEFICS) (Ahrens et al. 2011). Examination modules
comprised several questionnaires, physical examinations, and bi-
ological samples. The cohort profile has been described in detail
elsewhere (Ahrens et al. 2017).
Ethical considerations
Each participating center obtained ethical approval from the
local responsible authorities. Informed consent from the children
and their parents was required before any data collection and they
were free to reject single examination modules and questionnaires.
Study design and recruitment
An initial baseline examination (T0) in the context of the
abovementioned IDEFICS study—the data of which were not used
for this study as use of NUS was not recorded—took place from
2007 to 2008, followed by a first follow-up examination (T1) from
2009 to 2010, in at least two local not randomly selected commu-
nities per country. All children aged 2–9 years attending kinder-
garten and elementary school had been eligible. As part of the
subsequent I.Family study—which provided the data for this
study—children who participated in T0 and/or T1 of IDEFICS
(hereafter referred to as index children), as well as their parents and
siblings, were invited for a second follow-up. Thus, between 2013
and 2014, data were provided from 6167 families. For the present
cross-sectional analysis, all 5- to 17-year olds were eligible and we
selected one member from each family using an algorithm de-
scribed under the ‘‘Exclusion Criteria’’ section.
General information about the respondent or the family such as
sociodemographic characteristics was given by at least one parent
or legal guardian. Information on the medical history of the par-
ticipants, including diseases, drug use, and the intake of NUS, was
obtained from at least one parent living in the main household using
a computer-assisted personal or telephone interview.
Study measures
Participants were categorized as having ADHD depending on a
parent-reported diagnosis and/or use of any of the following
ADHD-approved medications: methylphenidate, atomoxetine,
2 SCHOLLE ET AL.
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amphetamine, dexamphetamine, lisdexamfetamine. Centrally act-
ing alpha-agonists (clonidine or guanfacine) were not approved for
ADHD in Europe during the study years. Details about the diag-
nosis, drug use, and use of NUS within the last 14 days were col-
lected using a questionnaire about chronic diseases diagnosed in the
individual participant. A subject with ADHD was categorized as
‘‘medicated’’ if at least one of the abovementioned ADHD-
approved medications had been used.
The study outcome was use of NUS, measured by use of (1) any
or (2) multiple different NUS (either simultaneously or sequen-
tially) during the last 14 days. The measure regarding multiple
different NUS reflecting a more intensive intake was added post
hoc to the protocol during the analysis, since we observed con-
spicuously high rates of the differently classified NUS (e.g., omega-
3 fatty acids and vitamin D) in unmedicated subjects with ADHD.
In addition to given categories of NUS, parents could specify ad-
ditional products, which interviewers entered as free text. Free-text
records were allocated to the respective categories; for example,
brand names from omega-3 products were assigned to ‘‘omega-3
fatty acids.’’ A pharmacist carried out the allocation using blinded
records, that is, without information on the ADHD diagnosis. This
was reviewed by one person from each participating country.
As covariates, we included characteristics shown by former
studies to be either associated with ADHD and/or use of NUS or
those hypothesized to be associated with any form of dietary in-
tervention (e.g., food intolerance). Use of prescription drugs (other
than ADHD medications) during the last 14 days was assessed from
free-text records on medication that were processed as described
for the NUS. The following parent-reported chronic diseases of the
child were included: food intolerance (e.g., to lactose, fish and
crustaceans, fruits and vegetables), serious infection requiring
hospitalization, and allergic diseases (e.g., eczema and hay fever).
Regarding parental psychiatric disorders, the interviewer asked
about psychological/psychiatric problems. The highest parental
education level was coded according to the 2011 International
Standard Classification of Education and further categorized into
low (0–2), medium (3–5), and high (6–8) (United Nations Educa-
tional, Scientific and Cultural Organization 2011). Income level
was categorized into five groups by linking the income to the av-
erage country-specific net household income.
Exclusion criteria
Subjects were excluded from the analysis if a completed ques-
tionnaire on health and medical history was not available. More-
over, to avoid any effects of familial clustering, we excluded
siblings using the following algorithm: participants who had been
diagnosed with ADHD were identified first and their siblings
without ADHD excluded. From families without any or more than
one ADHD subject, nonindex children were excluded. If more than
one index child was eligible, we randomly selected one.
Statistical analyses
Using descriptive statistics, sample characteristics and use of
NUS were shown for each of the three groups, namely children and
adolescents without ADHD (1) and those with ADHD who were
unmedicated (2) or medicated (3). Two multivariable logistic re-
gressions were used to identify group-dependent differences: first, a
partially adjusted model, controlling for the demographic variables
age, sex, and country, and second, a fully adjusted model, taking also
into account education level, income level, serious infections, al-
lergic diseases, food intolerance, and parental psychiatric disorders.
When considering education and income level as confounders,
missing values for these variables were treated as separate categories
and taken into account as dummy variables in the regression models.
An additional analysis was conducted to compare all subjects with
ADHD—independently of medication status—with non-ADHD
peers to evaluate the comparability of our estimates (fully adjusted)
with those obtained from the NHANES data. In addition, although
parent-reported ADHD diagnoses have shown convergent validity
(Visser et al. 2013), we attempted to corroborate the parent-reported
ADHD diagnoses in our study. Using the t-test, we compared subjects
with and without ADHD regarding mean differences in a score for
impulsiveness based on survey items. Higher scores indicate more
impulsive behavior of a subject according to the negative urgency
subscale of the UPPS Impulsive Behavior Scale (Cyders et al. 2007).
For all statistical programming, the analysis software SAS 9.3
(SAS Institute, Cary, NC) was used. For each parameter estimate, we
calculated raw (two sided) p-values and 95% confidence limits.
However, since the main focus of this study was based on four hy-
potheses regarding the influence of ADHD (medicated/unmedicated
vs. non-ADHD) on the use of any NUS (yes/no) and the use of
multiple different NUS, the (Bonferroni corrected) significance level
was considered to be a=0.05/4, that is, a null hypothesis was rejected
for each p£0.0125.
Results
After excluding siblings, 127 children and adolescents with
ADHD (51 medicated and 76 unmedicated) and 4940 without
ADHD were included in the cohort (Fig. 1).
Sample characteristics
The male-to-female sex ratio was 4.5:1 in all ADHD subjects
and higher in those medicated (Table 1). For both unmedicated and
medicated children and adolescents with ADHD, there was a 5-year
interval (mean) since the onset of ADHD. Use of non-ADHD
prescription drugs was higher in ADHD subjects.
Use of NUS
Any NUS use was reported by 20% (26/127) of those with
ADHD and by 18% (877/4940) of those without ADHD (Table 1).
Unmedicated subjects with ADHD (n = 76) had the highest per-
centages in almost all categories of NUS. In both groups, with and
without ADHD, multivitamin/multimineral complex products were
most frequently used. Use of at least two different NUS was 5%
among those without ADHD and 13% among unmedicated ADHD
subjects, while none of the 51 medicated ADHD subjects had use of
multiple NUS.
In unmedicated subjects with ADHD who used multiple dif-
ferent NUS (n = 10), omega-3 fatty acids and vitamin D were most
frequently used. In subjects without ADHD who used multiple
different NUS (n= 235), vitamin C was most frequently used
(54%). No melatonin use was reported as an NUS. This was ex-
pected as—in contrast to the United States—melatonin is rather
uncommon as an NUS in Europe; a 2 mg preparation is even ap-
proved as a prescription drug by the European Medicines Agency.
ADHD-dependent differences in using NUS
Compared with those without ADHD, unmedicated ADHD
subjects were more likely to use multiple different NUS (fully
adjusted odds ratio [OR], 2.6; 95% confidence interval [CI], 1.2–
5.6; Table 2). Participants who used non-ADHD prescription drugs
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(both ADHD and non-ADHD subjects) were more likely to use any
and multiple NUS.
Additional analyses
Regarding the comparison of all ADHD subjects with non-
ADHD peers, we found ORs similar to those from the NHANES
data (Gardiner et al. 2008). The OR regarding ADHD in our study
was 1.2; 95% CI, 0.7–2.0 compared with 1.1; 95% CI, 0.8–1.5 in
Gardiner et al. (2008) and the OR regarding use of prescription
drugs was 1.6; 95% CI, 1.2–2.1 compared with 1.4; 95% CI, 1.1–
1.7, respectively.
The comparison of subjects with and without ADHD regarding
impulsive behavior revealed that of those with an available score,
subjects with ADHD (n = 45) had higher scores ( p < 0.05) than
those without (n = 1989).
Discussion
This population-based study found a higher use of multiple
different NUS in unmedicated children and adolescents with
ADHD compared with medicated ones and those without ADHD.
An increased use of any NUS was not statistically significant for
both medicated and unmedicated ADHD subjects. Gardiner et al.
FIG. 1. Participant flow. ADHD, attention-deficit/hyperactivity disorder.
Table 1. Sample Characteristics and Nutritional Supplement Use by Group
No ADHD
ADHD
(n = 4940)
Unmedicated Medicated All cases
(n= 76) (n = 51) (n= 127)
Age in years, mean (SD) 11.6 (1.94) 11.7 (2.59) 11.4 (2.06) 11.6 (2.39)
Male sex, n (%) 2454 (49.7) 61 (80.3) 43 (84.3) 104 (81.9)
Years since onset,a mean (SD) NA 5 (3.2) 5 (3.2) 5 (3.2)
Use of non-ADHD prescription drugs, n (%) 441 (8.9) 10 (13.2) 8 (15.7) 18 (14.2)
Use of any nutritional supplement within 14 days, n (%) 877 (17.8) 17 (22.4) 9 (17.6) 26 (20.5)
Omega-3 fatty acids, n (%) 145 (2.9) 5 (6.6) 1 (2.0) 6 (4.7)
Vitamin C, n (%) 267 (5.4) 5 (6.6) 1 (2.0) 6 (4.7)
Vitamin D, n (%) 161 (3.3) 6 (7.9) 0 (0.0) 6 (4.7)
Vitamin B, n (%) 20 (0.4) 1 (1.3) 0 (0.0) 1 (0.8)
Multivitamin complex, n (%) 162 (3.3) 2 (2.6) 2 (3.9) 4 (3.1)
Multivitamin/multimineral complex,b n (%) 257 (5.2) 7 (9.2) 4 (7.8) 11 (8.7)
Other minerals, n (%) 138 (2.8) 4 (5.3) 0 (0.0) 4 (3.1)
Other nutritional supplements, n (%) 37 (0.7) 2 (2.6) 1 (2.0) 3 (2.4)
Use of multiple different nutritional supplements from above,c n (%) 235 (4.8) 10 (13.2) 0 (0.0) 10 (7.9)
aBased on those unmedicated (n= 68) and medicated (n= 30) with available information.
bMore than one vitamin and more than one mineral.
cEither simultaneously or sequentially within 14 days. In unmedicated subjects with ADHD who used multiple different nutritional supplements
(n= 10), omega-3 fatty acids and vitamin D were most frequently used.
ADHD, attention-deficit/hyperactivity disorder; NA, not applicable; SD, standard deviation.
4 SCHOLLE ET AL.
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(2008) also used population-based survey data to estimate preva-
lence of and common factors for use of any NUS. As in our study,
not ADHD, but use of prescription drugs was strongly associated
with use of any NUS. Similar to our study, multivitamins and vi-
tamin C were most commonly used underlining the comparability
of our results with those from the NHANES data analyzed by
Gardiner et al. (2008). The overall prevalence of use of any NUS
was, however, higher in their study. This might be because they
enquired about use in the prior month, compared with the last 2
weeks in our study.
We hypothesized that the suggested association between ADHD
and use of NUS may depend on ADHD medication treatment, since
use of prescription drugs in general was a predictor of use of any
NUS (Gardiner et al. 2008). In our sample, the point estimate in-
dicated that subjects with medicated ADHD were 50% more likely
to use any NUS; however, due to the small number of children with
medicated ADHD, the corresponding wide CI does not allow any
reliable conclusions.
Interestingly, we found that use of multiple different NUS in
ADHD subjects occurred only in those who were not taking ADHD
medication. Consequently, we added this variable as a second
measure for the primary outcome, thereby enhancing the reflection
of utilization habits. On the one hand, the observed association
between use of multiple NUS and unmedicated ADHD was sur-
prising as using prescription drugs in general was a predictor for use
of any NUS. On the other hand, this finding is in line with results
from Sinha and Efron (2005). They showed that ‘‘additional benefit
to doctor’s treatment’’ was one of the main reasons (70%) to use
complementary and alternative medicine in children with ADHD,
however, a ‘‘benefit in place of doctor’s treatment’’ was still in-
dicated in 30% of the surveyed parents (Sinha and Efron 2005).
It is possible that we identified—for the first time in a
population-based sample—such a subgroup of children and ado-
lescents with ADHD who received parent-initiated self-care in-
terventions with multiple different NUS in place of medication. At
first glance, the proportion of 13% of unmedicated children and
adolescents with ADHD who potentially received this intervention
appears relatively small. However, given both the epidemiology of
ADHD and its correlates and sequelae, it is a notable amount from a
public health point of view. Assuming that ADHD medication
would have been indicated in these subjects, this therapeutic at-
tempt should be assessed critically.
Unmedicated children and adolescents with ADHD who used
multiple different NUS in our study mainly took omega-3 fatty acids
and vitamin D. The NICE committee concluded that omega-3 fatty
acids had no clinically important benefits for ADHD and, due to lack
of data on side effects, that harm could not be excluded (NICE 2018).
A later systematic review aimed to examine effects of omega-3
supplementation on cognition in the general population and in those
with neurodevelopmental disorders. The authors concluded that
there is no evidence for an effect on cognition in both population
groups and that advertisement claims of cognitive benefits should be
narrowed (Cooper et al. 2015). The same authors concluded in an-
other review that the possibility of moderate to large effects on
reducing emotional dysregulation, oppositional behavior, and con-
duct problems (which commonly accompany ADHD) by omega-3
fatty acid supplementation can be ruled out (Cooper et al. 2016).
However, omega-3 fatty acids might be used as an adjunct
therapy to ADHD medication to reduce the dosage (Ko¨nigs and
Kiliaan 2016; Lange et al. 2017), for subjects with subclinical
symptoms (Sonuga-Barke 2015), or by families who decline other
psychopharmacological options (Bloch and Qawasmi 2011). There
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is hypothetical evidence for the efficacy of vitamin D supplementa-
tion in patients with psychiatric disorders on improving brain func-
tions (Patrick and Ames 2015). However, clinical evidence is only
available for the effect of vitamin D supplementation on improving
ADHD evening symptoms when it is used adjunctively to methyl-
phenidate but not as monotherapy (Mohammadpour et al. 2016).
In addition to the limited evidence on the effectiveness of NUS
in unmedicated ADHD patients, consumers in the countries par-
ticipating in this study usually have to pay for NUS as they are
normally not reimbursed by health insurances. This might result in
a potentially unnecessary financial burden for families who have a
child with ADHD. These families already have a high burden due to
the effects of ADHD on family life (Le et al. 2014). Undoubtedly,
the generally smaller effect size (Sonuga-Barke et al. 2013; Ste-
venson et al. 2014; Faraone et al. 2015) of a single administered
NUS to treat ADHD, if proven ineffective, should not lead to at-
tempts of enhancing the effect with additional supplements.
As an alternative to combining single conventional NUS, for
example, omega-3 fatty acids with vitamin D as in our study, there
is a growing base of literature suggesting that carefully balanced,
highly bioavailable multivitamin/multimineral supplements may
be beneficial at least for some comorbid children with ADHD
(Rucklidge et al. 2018). A recent—first and yet to be confirmed—
randomized placebo-controlled study indicated reduction of debili-
tating symptoms such as emotional dysregulation and aggression by
a 48-ingredient micronutrient formula (Rucklidge et al. 2018).
In reviewing the literature, it can be assumed that at least one of
three parents does not inform their pediatrician about child’s use of
complementary and alternative medicine (Chan et al. 2003; Sinha
and Efron 2005) and a delay in ADHD treatment due to its use is
reportedly common (Vohra et al. 2009; Hurt and Arnold 2014).
Research has shown an increased willingness to use medical and
psychosocial interventions to treat ADHD among parents and ad-
olescents who felt knowledgeable and among those who considered
the treatments acceptable and helpful (Bussing et al. 2012). Hence,
the clinical implication of our findings is that pediatricians should
actively explore whether parents/patients favor orally administered
NUS over medication to treat ADHD core symptoms and, if nec-
essary, emphasize that based on current evidence the average effect
size of ADHD medication is larger. In case that families decline
psychopharmacological options and prefer NUS, recommendations
should optimally be given according to best available evidence.
The main strength of our study lies in the large population-based
approach, avoiding clinical sampling biases and improving the sta-
tistical certainty of our findings. Another strength is that our data
allowed us to differentiate between subjects with medicated and
unmedicated ADHD. However, our study has some limitations. First,
we did not have information on psychosocial interventions such as
behavioral therapy and therefore could only focus on oral remedies
(i.e., ADHD medication and NUS). Second, we did not know when
the patient had last visited the pediatrician and whether a nutrient
deficiency existed possibly justifying use of multiple different NUS.
Third, we were not able to assess the severity of ADHD.
Fourth, the calculated prevalence of ADHD in the included
sample is somewhat lower than the worldwide prevalence reported
in the meta-analysis by Polanczyk et al. (2015). Reasons might be
that our prevalence can be considered an administrative prevalence
(reported diagnosis), unwillingness to admit a psychiatric disorder
in one’s child by a parent to the interviewer, and generally lower
prevalence rates according to the criteria of the International
Classification of Diseases—which is more common in Europe—
than according to the Diagnostic and Statistical Manual of Mental
Disorders (Do¨pfner et al. 2008). As the sample of children and
adolescents with ADHD is rather small, our interpretations need to
be treated with care.
Fifth, parents were only asked for current use of medication.
Hence, we do not know whether children who were unmedicated at
the time of the study had been medicated in the past. ADHD
medication might have not been effective/tolerated and therefore
alternative treatments could have been chosen. In addition, we do
not know whether unmedicated subjects in our sample benefited
from NUS.
Finally, as the study was conducted in several countries, our data
were structured hierarchically. Typically, multilevel logistic re-
gression models should be used to counteract false inferences. Our
model did not converge for the outcome ‘‘use of multiple nutri-
tional supplements.’’ Therefore, we decided on a conventional lo-
gistic regression model. However, both models resulted in
equivalent findings with the outcome ‘‘any nutritional supplement’’
and research suggests that, given a small number of countries, and
when interested in the effect of characteristics on the individual
level as in our study, the hierarchical structure can be ignored
(Austin et al. 2003; Bryan and Jenkins 2016).
Conclusions
The results of this study suggest that a notable proportion of
unmedicated children and adolescents with ADHD—or presum-
ably rather their parents—prefer a treatment strategy of using
multiple different NUS rather than ADHD medication. As all
studied NUS had to be taken orally, this subgroup obviously did not
avoid oral remedies in general. The findings in this study add to a
growing body of literature on complementary and alternative
medicine use in children and adolescents with ADHD suggesting
that NUS are potentially taken inappropriately as treatment for
ADHD. This study confirmed this fact, for the first time, in a
population-based sample and by including a comparison group.
Pediatricians should actively enquire in routine care about parent-
initiated self-care interventions with NUS at an early stage and
provide both the patient and the parent/caregiver with evidence-
based patient information about pharmacological and other non-
pharmacological ADHD treatments.
Clinical Significance
This is the first study that showed differences in use of NUS
depending on ADHD and medication status in a population-based
sample. Unmedicated ADHD children and adolescents are more
likely to use multiple different NUS compared with medicated and
non-ADHD peers. This finding suggests that a notable proportion
of children and adolescents with ADHD or their parents prefer a
treatment strategy of taking multiple NUS instead of ADHD med-
ication.
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